PMID- 25087508 OWN - NLM STAT- MEDLINE DCOM- 20150514 LR - 20140901 IS - 1873-3476 (Electronic) IS - 0378-5173 (Linking) VI - 473 IP - 1-2 DP - 2014 Oct 1 TI - Low-dose capsule filling of inhalation products: critical material attributes and process parameters. PG - 617-26 LID - S0378-5173(14)00549-3 [pii] LID - 10.1016/j.ijpharm.2014.07.050 [doi] AB - The aim of the present work was to identify the material attributes and process parameters of a dosator-nozzle capsule filling machine that are critical in low-fill weight capsule filling for inhalation therapies via hard-gelatin capsules. Twelve powders, mostly inhalation carriers, some fines and one proprietary active pharmaceutical ingredient (API), were carefully characterized and filled into size 3 capsules. Since different process conditions are required to fill capsules with powders that have very different material attributes, the powders were divided into two groups. A design of experiments (DOE) based exclusively on process parameters was developed for each group, to identify the critical material attributes (CMA) and critical process parameters (CPP). The fill weight (4-45 mg) of the group I powders (larger particles, higher density, better flowability and less cohesion) correlated with the nozzle diameter (1.9-3.4mm), the dosing chamber length (2.5-5mm), the powder layer depth (5-12.5mm) and the powder density (bulk and tapped density). The RSDs were acceptable in most cases, even for very low doses. The fill weight (1.5-21 mg) of group II powders (very fine and low dense particles with a particle size <10 mum, poor flowability and higher cohesion) depended also on the nozzle diameter (1.9-2.8mm), the dosing chamber length (2.5-5mm) and the powder layer depth (5-10mm), albeit in a different way, indicating that for these powders dosator filling was not volumetric. Moreover, frictional (wall friction angle) and powder-flow characteristics (bulk density and basic flowability energy) have an influence on the mass. Thus, in summary, group I and group II powders can be filled successfully via dosator systems at low fill weights. However, the group II powders were more challenging to fill, especially without automated process control. This study is the first scientific qualification of dosator nozzles for low-fill weight (1-45 mg) capsule filling. CI - Copyright (c) 2014 Elsevier B.V. All rights reserved. FAU - Faulhammer, Eva AU - Faulhammer E AD - Technical University, Inffeldgasse 13, 8010 Graz, Austria; Research Center Pharmaceutical Engineering, Inffeldgasse 13, 8010 Graz, Austria. FAU - Fink, Marlies AU - Fink M AD - Technical University, Inffeldgasse 13, 8010 Graz, Austria; Research Center Pharmaceutical Engineering, Inffeldgasse 13, 8010 Graz, Austria. FAU - Llusa, Marcos AU - Llusa M AD - Research Center Pharmaceutical Engineering, Inffeldgasse 13, 8010 Graz, Austria. FAU - Lawrence, Simon M AU - Lawrence SM AD - GlaxoSmithKline (GSK), New Frontiers Science Park, Harlow, Essex CM19 5AW, UK. FAU - Biserni, Stefano AU - Biserni S AD - MG2, Via del Savena 18, I-40065, Pian di Macina di Pianoro, Bologna, Italy. FAU - Calzolari, Vittorio AU - Calzolari V AD - MG2, Via del Savena 18, I-40065, Pian di Macina di Pianoro, Bologna, Italy. FAU - Khinast, Johannes G AU - Khinast JG AD - Technical University, Inffeldgasse 13, 8010 Graz, Austria; Research Center Pharmaceutical Engineering, Inffeldgasse 13, 8010 Graz, Austria. Electronic address: khinast@tugraz.at. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140801 PL - Netherlands TA - Int J Pharm JT - International journal of pharmaceutics JID - 7804127 RN - 0 (Capsules) RN - 0 (Powders) RN - 3OWL53L36A (Mannitol) RN - J2B2A4N98G (Lactose) SB - IM MH - Administration, Inhalation MH - *Capsules MH - Lactose/chemistry MH - Mannitol/chemistry MH - Powders/*chemistry MH - Technology, Pharmaceutical/*methods OTO - NOTNLM OT - Critical quality attributes OT - Dosator nozzle machine OT - Inhalation powders OT - Low-dose capsule filling OT - Low-fill weight OT - Multivariate data analysis EDAT- 2014/08/05 06:00 MHDA- 2015/05/15 06:00 CRDT- 2014/08/05 06:00 PHST- 2014/06/20 00:00 [received] PHST- 2014/07/23 00:00 [revised] PHST- 2014/07/26 00:00 [accepted] PHST- 2014/08/05 06:00 [entrez] PHST- 2014/08/05 06:00 [pubmed] PHST- 2015/05/15 06:00 [medline] AID - S0378-5173(14)00549-3 [pii] AID - 10.1016/j.ijpharm.2014.07.050 [doi] PST - ppublish SO - Int J Pharm. 2014 Oct 1;473(1-2):617-26. doi: 10.1016/j.ijpharm.2014.07.050. Epub 2014 Aug 1.